Oxford Endovascular: Revolutionizing Brain Aneurysm Treatment
May 21, 2024, 9:30 am
Oxford Endovascular, a spinout from Oxford University, has secured £8 million in funding to advance its groundbreaking brain aneurysm technology. The company's innovative device, OXIFLOW, aims to reduce the occurrence of brain hemorrhage by treating intracranial aneurysms with precision and reliability.
Oxford Endovascular, founded in 2015, is on a mission to transform the landscape of brain aneurysm treatment. Their flow-diverter stent, OXIFLOW, is a miniature device crafted from Nitinol, a cutting-edge nickel titanium alloy known for its superior design capabilities. Unlike traditional flow-diverters, OXIFLOW is engineered to conform seamlessly to the patient's blood vessels, minimizing the risk of complications associated with current treatments.
With the recent £8 million funding round led by Parkwalk Advisors, Oxford Endovascular is poised to take OXIFLOW to the next level. This investment will propel the company towards conducting First-In-Human trials, bringing them one step closer to revolutionizing brain aneurysm treatment on a global scale.
CEO Mike Karim expressed his gratitude for the support of their investment partners, emphasizing the team's dedication to realizing their vision of transforming brain aneurysm treatment. As they gear up for human trials, Oxford Endovascular is collaborating closely with regulators, physicians, and industry experts to pave the way for OXIFLOW's market debut.
The unique design and engineering prowess of OXIFLOW have garnered recognition and financial backing from prestigious entities such as Horizon Europe, Innovate UK, and the EU's EIT-funded Covid rescue program. This further underscores the potential impact of Oxford Endovascular's innovative approach to tackling brain aneurysms.
Investment Director Alun Williams of Parkwalk Advisors commended Oxford Endovascular for their commitment to pushing the boundaries of medical technology. By investing in research-intensive companies with the potential for transformative breakthroughs, Parkwalk Advisors is proud to support Oxford Endovascular in their mission to improve lives and make a positive societal impact.
As Oxford Endovascular continues to make strides in the field of brain aneurysm treatment, their latest funding round signifies a significant milestone in their journey towards bringing OXIFLOW to patients in need. With a strong network of investors and collaborators backing their vision, Oxford Endovascular is poised to revolutionize the way we approach and treat this critical medical condition.
Oxford Endovascular, founded in 2015, is on a mission to transform the landscape of brain aneurysm treatment. Their flow-diverter stent, OXIFLOW, is a miniature device crafted from Nitinol, a cutting-edge nickel titanium alloy known for its superior design capabilities. Unlike traditional flow-diverters, OXIFLOW is engineered to conform seamlessly to the patient's blood vessels, minimizing the risk of complications associated with current treatments.
With the recent £8 million funding round led by Parkwalk Advisors, Oxford Endovascular is poised to take OXIFLOW to the next level. This investment will propel the company towards conducting First-In-Human trials, bringing them one step closer to revolutionizing brain aneurysm treatment on a global scale.
CEO Mike Karim expressed his gratitude for the support of their investment partners, emphasizing the team's dedication to realizing their vision of transforming brain aneurysm treatment. As they gear up for human trials, Oxford Endovascular is collaborating closely with regulators, physicians, and industry experts to pave the way for OXIFLOW's market debut.
The unique design and engineering prowess of OXIFLOW have garnered recognition and financial backing from prestigious entities such as Horizon Europe, Innovate UK, and the EU's EIT-funded Covid rescue program. This further underscores the potential impact of Oxford Endovascular's innovative approach to tackling brain aneurysms.
Investment Director Alun Williams of Parkwalk Advisors commended Oxford Endovascular for their commitment to pushing the boundaries of medical technology. By investing in research-intensive companies with the potential for transformative breakthroughs, Parkwalk Advisors is proud to support Oxford Endovascular in their mission to improve lives and make a positive societal impact.
As Oxford Endovascular continues to make strides in the field of brain aneurysm treatment, their latest funding round signifies a significant milestone in their journey towards bringing OXIFLOW to patients in need. With a strong network of investors and collaborators backing their vision, Oxford Endovascular is poised to revolutionize the way we approach and treat this critical medical condition.